Slideshow

Reassess Prescription Drug Use after a Fracture

“Not treating patients with osteoporosis drugs after a fracture would be like discharging a patient after a myocardial infarction without drugs to prevent a subsequent infarction,” researchers write in JAMA Internal Medicine.

A study in the Aug. 22 issue of JAMA Internal Medicine finds that more than 85% of patients who experienced a hip, humerus or wrist fracture, were still taking one or more drugs known to increase fracture risk or decrease mineral bone density - four months after the initial fracture. Patients who have had a fracture are at high risk of subsequent falls and fracture. So, reducing psychotropic medications and prescribing medications that can prevent fractures, could reduce fractures in this high-risk group, researchers reported. In this slideshow, we highlight some key points from the study.

References:

Sarah D. Berry, MD; Douglas P. Kiel, MD.

"Medication Review After a Fracture-Absolutely Essential,"

JAMA Internal Medicine.

Aug. 22, 2016. DOI:10.1001/jamainternmed.2016.4822  Jeffrey C. Munson, MD, Julie P. W. Bynum, MD, et. al.

"Patterns of Prescription Drug Use Before and After Fragility Fracture,"

Aug. 22, 2016.

JAMA Internal Medicine

. DOI:10.1001/jamainternmed.2016.4814  

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.